Parmax Pharma Ltd

📉 Parmax Pharma Q3 FY2025 Results: Revenue Drops, Losses Widen

• Q3 2025 revenue: ₹43.26 million (down from ₹62.84 million in Q3 2024).

• Nine-month revenue: ₹87.99 million (significant decrease from ₹233.78 million last year).

• Q3 2025 net loss: ₹7.32 million (vs. ₹3.95 million loss in Q3 2024).

• Nine-month net loss: ₹35.75 million (widened from ₹5.99 million).

• Basic EPS for Q3: negative ₹1.96; nine-month EPS: negative ₹9.55.

• Insurance claim of ₹35 million pending for December 2023 fire incident.

• Depreciation not charged on clean room and effluent treatment plants due to non-use.